Cypre Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
2ndary - Private
- Investors
-
3
Cypre General Information
Description
Developer of hydrogel patterning technology and a model designed to improve the process of cancer drug development and precision medicine. The company's platform utilizes patented three-dimensional bioprinting technology and proprietary methods that synergize with high-content imaging to assay immunotherapy efficacy, enabling medical institutions to identify therapeutics that overcome cancer immunotherapy resistance.
Contact Information
Website
www.cypre.comCorporate Office
- 135 Mississippi Street
- San Francisco, CA 94107
- United States
Corporate Office
- 135 Mississippi Street
- San Francisco, CA 94107
- United States
Cypre Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 3. Seed Round | 10-Jan-2024 | Completed | Generating Revenue | |||
| 2. Seed Round | 01-Feb-2017 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | 01-Jan-2016 | Completed | Startup |
Cypre Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-6 | ||||||||
| Seed-5 | ||||||||
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 120,919 | $0.000100 | $1.67 | $1.67 | 1x | $1.67 | 2.81% | |
| Seed-1 | 231,196 | $0.000100 | $1.05 | $1.05 | 1x | $1.05 | 5.36% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cypre Patents
Cypre Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024527413-A | Compositions and methods for improving cancer treatment | Pending | 15-Jul-2021 | ||
| JP-2026027314-A | Compositions and methods for improving the treatment of cancer | Pending | 15-Jul-2021 | ||
| AU-2022311934-A1 | Compositions and methods for improving treatment of cancer | Inactive | 15-Jul-2021 | ||
| EP-4370921-A1 | Compositions and methods for improving treatment of cancer | Inactive | 15-Jul-2021 | ||
| EP-4370921-A4 | Compositions and methods for improving treatment of cancer | Inactive | 15-Jul-2021 | A61K40/42 |
Cypre Signals
Cypre Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kluz Ventures | Venture Capital | Minority | ||
| NOVIT Ventures | Corporate Venture Capital | Minority | ||
| MBC BioLabs | Accelerator/Incubator | Minority |
Cypre FAQs
-
When was Cypre founded?
Cypre was founded in 2016.
-
Where is Cypre headquartered?
Cypre is headquartered in San Francisco, CA.
-
What is the size of Cypre?
Cypre has 7 total employees.
-
What industry is Cypre in?
Cypre’s primary industry is Biotechnology.
-
Is Cypre a private or public company?
Cypre is a Private company.
-
What is Cypre’s current revenue?
The current revenue for Cypre is .
-
How much funding has Cypre raised over time?
Cypre has raised $1.68M.
-
Who are Cypre’s investors?
Kluz Ventures, NOVIT Ventures, and MBC BioLabs have invested in Cypre.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process